Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation

Published 03/15/2021, 11:20 PM
Updated 07/09/2023, 06:31 AM
LLY
-
BIIB
-
PFE
-

Shares of Eli Lilly LLY fell more than 9% on Mar 15 after it announced data on secondary endpoints of its phase II study — TRAILBLAZER-ALZ. Earlier in January, the company had announced that the study, which evaluated its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease (“AD”), has met its primary endpoint. However, the latest data on certain secondary endpoints failed to meet the expectations of investors, which led to the decline in the stock.

Lilly’s shares have gained 12.1% so far this year against the industry’s decline of 0.6%.

Data from the study, announced in January, showed that treatment with donanemab slowed disease progression significantly by 32% compared to placebo, as measured on the integrated Alzheimer's Disease Rating Scale (iADRS), over a treatment period of 76 weeks. The measurement on iADRS, a novel and composite measure of cognition and daily function, was the primary endpoint of the study.

Updated data from the study announced last week showed consistent slowing of cognitive and functional decline as measured by Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13) during the final analysis. These two scales are more widely used measurements for Alzheimer's disease patients and were included in the study’s secondary endpoints. Although treatment with donanemab consistently slowed the decline as measured on these two scales and achieved nominal statistical significance multiple times compared to placebo during the study, it failed to maintain the statistical significance during the final analysis after 76 weeks of treatment.

The company and the investors diverge on the analysis of the data, as Lilly is focusing on the iADRS while the investors chose the widely-accepted CDR-SB and ADAS-Cog13 scales for their understanding.

Moreover, investors are skeptical about the iADRS measurement due to Lilly’s past performance with its discontinued AD candidate, solanezumab. This candidate also performed better when measured in iADRS, but CDR-SB scores were not that encouraging. The candidate failed in the late-stage study.

Meanwhile, Lilly believes that donanemab holds potential as a therapy for treating AD patients as it consistently slowed cognitive and functional decline across all primary and secondary endpoints. The company also defended its usage of iADRS as the primary endpoint instead of the CDR-SB scale by stating that it believes iADRS to be a more consistent and sensitive measure to detect treatment differences than other Alzheimer's disease scales.

The company is also evaluating the candidate in a pivotal phase II study — TRAILBLAZER-ALZ 2. Following the TRAILBLAZER-ALZ study data readout, the company is changing the study designation to phase III and increasing the enrollment target to 1,000. It is also changing the primary endpoint of the study to iADRS from the current CDR-SB scale. The company shifted the CDR-SB scale to the secondary endpoints list.

Future, data readouts from the TRAILBLAZER-ALZ 2 study will provide more clarity on the potential of donanemab as an AD therapy. However, AD is one of the toughest diseases to be treated. While there is no cure for the disease yet, there are a few drugs approved by the FDA that can help control the symptoms of AD. One of the leading contenders in the AD segment is Biogen’s BIIB controversial investigational treatment for Alzheimer’s disease — aducanumab — which is under review with the FDA. A decision is expected this month. We note that an FDA advisory committee has voted against approving aducanumab last year in November. Several other companies have terminated their AD programs after years of failure, including Merck MRK and Pfizer PFE.

Zacks Rank

Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

AccessZacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (NASDAQ:BIIB): Free Stock Analysis Report

Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.